From 13 studies the pooled HR for glargine vs no use of glargine was 1.04 (95 % CI 0.91, 1.17; p = 0.49) (Fig. 3 and Table 3), showing no evidence for an association between insulin glargine treatment and increased incidence of breast cancer. The gene discussed is INS; the disease is breast carcinoma.